Geeta Sharma
Research Subjects
Geeta Sharma has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Anna Rutkowska
Cellzome, a GSK Company, R&D, GSK, Heidelberg, Germany
68 shared publications - H. Christian Eberl
Cellzome, a GSK company, Meyerhofstrasse 1, 69117 Heidelberg, Germany
68 shared publications - Marcus Bantscheff
Cellzome, A GSK company
68 shared publications - Thilo Werner
Cellzome, GSK, R&D, Heidelberg, Germany. 1
68 shared publications - Amalia Martinez-Segura
Genomic Sciences, R&D, GSK, Heidelberg, Germany. 2
54 shared publications - Bin Feng
Precision Medicine, R&D, GSK, Waltham, Massachusetts
54 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This file contain information on the Cell lines and organoids used in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This file contain information on the Cell lines and organoids used in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This file contains details of the BE sgRNA library
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This file contains details of the BE sgRNA library
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-6 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
Supplementary Figure 1. Generating base editor-expressing MSI cell lines for screening. Supplementary Figure 2. Quality control for base-editor screens in MSI cell lines. Supplementary Figure 3. Discovery and characterization of novel inhibitors of WRN helicase. Supplementary Figure 4. Correlation of WRN inhibitor sensitivity with genetic and molecular markers in MSI models. Supplementary Figure 5. Comparative analysis of DNA damage in MSI and MSS cells treated with WRN inhibitors and genetic inactivation. Supplementary Figure 6: Effects of GSK_WRN4 on MSI and MSS colorectal cancer xenografts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-6 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
Supplementary Figure 1. Generating base editor-expressing MSI cell lines for screening. Supplementary Figure 2. Quality control for base-editor screens in MSI cell lines. Supplementary Figure 3. Discovery and characterization of novel inhibitors of WRN helicase. Supplementary Figure 4. Correlation of WRN inhibitor sensitivity with genetic and molecular markers in MSI models. Supplementary Figure 5. Comparative analysis of DNA damage in MSI and MSS cells treated with WRN inhibitors and genetic inactivation. Supplementary Figure 6: Effects of GSK_WRN4 on MSI and MSS colorectal cancer xenografts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This table lists the results from Base editing screen
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
This table lists the results from Base editing screen
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S9 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Expression proteomic signature
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Expression proteomic signature
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Photo affinity labelling (PAL)
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Photo affinity labelling (PAL)
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Table S8 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Table S8 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Selectivity profile live cells (2D-TPP)
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Selectivity profile live cells (2D-TPP)
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
PanPARP matrix (affinity enrichment chemoproteomics)
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
PanPARP matrix (affinity enrichment chemoproteomics)
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Detection of 24,25-epoxycholesterol
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation
Detection of 24,25-epoxycholesterol